Exposure to avian coronavirus vaccines is associated with increased levels of <scp>SARS‐CoV</scp>‐2‐cross‐reactive antibodies

Ardicli, Ozge; Çarlı, K. Tayfun; Satitsuksanoa, Pattraporn; Dreher, Anita; Cusini, Alexia; Hutter, Sandra; Mirer, David; Rückert, Beate; Jónsdóttir, Hulda R.; Weber, Benjamín; Cervia, Carlo; Akdiş, Mübeccel; Boyman, Onur; Eggel, Alexander; Brüggen, Marie‐Charlotte; Akdiş, Cezmi A.; Veen, Willem van de

doi:10.1111/all.15441

Cited by 2 publications

(2 citation statements)

References 51 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A visible antibody cross‐reactivity was reported in infectious bronchitis virus, a non‐SARS‐CoV‐2 infection and chicken aerosol vaccines particularly in highly exposed veterinarians who administered the vaccines. However, this immune cross‐reactivity did not show a viral neutralizing activity and focused on non‐RBD antibodies, which substantially differ between SARS‐CoV‐2 and non‐SARS‐CoVs 179 …”

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 91%

See 1 more Smart Citation

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

Self Cite

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.

show abstract

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 91%

“…However, this immune cross‐reactivity did not show a viral neutralizing activity and focused on non‐RBD antibodies, which substantially differ between SARS‐CoV‐2 and non‐SARS‐CoVs. 179 …”

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 99%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

Evaluation of Commercial Infectious Bronchitis Virus Enzyme-Linked Immunoassay Kits

Tan,

Wang

2023

Taiwan Vet J

View full text Add to dashboard Cite

In Taiwan, infectious bronchitis virus (IBV) is mainly restricted to two groups Taiwan Group I (TW-I) and Taiwan Group II (TW-II) that are distinct from other countries. To evaluate the reliability of commercial enzyme-linked immunosorbent assay (ELISA) kits, imported commercial test kits (namely, A, B and C) were used to test field samples. The results were further compared with hemagglutination inhibition (HI) test to figure out the consistency. Results showed that the three commercial ELISA kits had only partial consistency with HI results. In fact, testing results of breeders and layers bore resemblance to HI, whereas there were ELISAs negatively detecting results of broilers opposed in HI. The specificities of these ELISA kits were 0.45, 0.86 and 0.77 for kits A, B and C, respectively, and their sensitivities were 0.79, 0.68 and 0.70, respectively. The commercial ELISA kits may not sustainably provide us the whole view of birds infected or vaccinated status. Based on the results of in-house ELISA and western blot, different IBV strains showed different antigen–antibody interaction. Thus, different ELISA coatings with different antigens might result in different antibody titers. Furthermore, according to HI results, 91% (256) and 70% (198) of the 282 tested sera were positive to H120 (as a Massachusetts vaccine) and 3263/04 (as a field strain), respectively. These high positive rates indicate that in spite of popular use of Massachusetts vaccines, the chickens are still commonly infected with field IBVs in Taiwan.

show abstract

Exposure to avian coronavirus vaccines is associated with increased levels of SARS‐CoV‐2‐cross‐reactive antibodies

Abstract: Ardicli and Carli contributed equally to the study.

Cited by 2 publications

References 51 publications

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID‐19

Evaluation of Commercial Infectious Bronchitis Virus Enzyme-Linked Immunoassay Kits

Contact Info

Product

Resources

About